About this approach
Bispecific antibodies are laboratory-made proteins designed to bind two targets. Some bring an immune cell close to a cancer cell; others block two cancer-related signals. The exact drug, target, cancer type, treatment line, and biomarker determine whether this treatment is appropriate.
Where it fits: Targeted immune therapy for selected blood cancers and solid tumors
Where this treatment is used
Multiple bispecific antibodies have FDA approval for defined settings, including certain leukemias, lymphomas, multiple myeloma, and lung cancers. Approval and evidence are drug-specific.
Procedure and practical considerations
Cytokine release syndrome, neurologic effects, infections, low blood counts, and infusion or injection reactions can occur, with risks varying by drug. Some treatments require step-up dosing, observation, preventive medicines, or hospitalization.
Clinics reporting this approach
These clinic profiles mention this approach in their published materials. Open a profile to compare locations, services, practical details, and ways to get started.
Sources
Source information checked: 2026-10-07. The links below identify the public and clinic-provided materials used for this page.
Compiled by: Cancer Clinic Finder Editorial Team
- NCI: Monoclonal Antibodies ↗Checked 2026-10-07
- FDA: Amivantamab approval for selected NSCLC ↗Checked 2026-10-07
How Cancer Clinic Finder compiles information · Suggest a factual correction
